Jonathan McNeill, Chief Business Officer at Dyne Therapeutics, Inc. (DYN), sold 1,261 shares at $9.41 ($12K) on 2023-09-18, disclosed to the SEC on 2023-09-20.
Scheduled sale ($12k) by Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| DYN | SELL | 2024-08-20 | $122K | — | Filing → |
| DYN | SELL | 2024-06-11 | $114K | — | Filing → |
| DYN | SELL | 2024-05-17 | $143K | — | Filing → |